Enoxaparin sodium
- PDF / 170,266 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 21 Downloads / 182 Views
1 S
Reactive thrombocytosis: case report A 57-year-old woman developed reactive thrombocytosis during anticoagulant therapy with enoxaparin sodium. The woman, who presented to the cardiac ICU due to chest pain, shortness of breath and excessive sweating, was diagnosed with a triple vessel disease. She then received a percutaneous coronary intervention to the left anterior descending artery using a drugeluting stent. On hospital day 4, she developed reactive thrombocytosis after the procedure with a platelet count of 491 × 1000 cells/µL. On hospital day 7, her platelet count was found to be increased at 596 × 1000 cells/µL. Her other laboratory values like WBC count and differential count were normal except for haemoglobin (9.8 g/dL). On a detailed analysis of her drug chart, it was noted that the platelet count had started increasing soon after the use of SC enoxaparin sodium [Lupinox; dosage not stated] injection. Prior to the initiation of SC enoxaparin sodium injection (i.e. on hospital day 2), her platelet count was 376 × 1000 cells/µL. She had no known drug allergies. Following the assessment using World Health Organization–Uppsala Monitoring Centre (WHO–UMC) scale and Naranjo causality assessment scale, it was concluded that enoxaparin sodium was the "probable" cause for reactive thrombocytosis. On hospital day 8, the woman’s enoxaparin-sodium was discontinued and a decrease in platelet count was observed. Since there were no complications associated with reactive thrombocytosis, no additional therapy was preferred, and she was discharged on the next day. Meenpidiyil SS, et al. Enoxaparin induced reactive thrombocytosis: A rare adverse drug reaction. Journal of Basic and Clinical Physiology and Pharmacology 31: No. 5, 2020. 803507252 Available from: URL: http://doi.org/10.1515/jbcpp-2019-0312
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
Data Loading...
